Kiniksa Pharmaceuticals International Plc’s filing revealed that its Officer Moat Ross acquired Company’s shares for reported $1.61 million on Apr 29 ’25. In the deal valued at $25.21 per share,64,035 shares were bought.
Then, Ragosa Mark bought 42,000 shares, generating $1,075,827 in total proceeds.
Before that, Moat Ross sold 18,259 shares. Kiniksa Pharmaceuticals International Plc shares valued at $370,475 were divested by the CHIEF COMMERCIAL OFFICER at a price of $20.29 per share. As a result of the transaction, Moat Ross now holds 9,415 shares, worth roughly $0.24 million.
Citigroup initiated its Kiniksa Pharmaceuticals International Plc [KNSA] rating to a Buy in a research note published on March 13, 2025; the price target was $40. A number of analysts have revised their coverage, including Jefferies’s analysts, who began to cover the stock in mid September with a ‘”a Buy”‘ rating. Wells Fargo began covering KNSA with “an Overweight” recommendation on May 03, 2024. BofA Securities maintained its rating on June 29, 2020. It rated KNSA as “a Buy”.
Price Performance Review of KNSA
On Tuesday, Kiniksa Pharmaceuticals International Plc [NASDAQ:KNSA] saw its stock jump 20.54% to $25.88. Over the last five days, the stock has gained 29.27%. Kiniksa Pharmaceuticals International Plc shares have risen nearly 30.84% since the year began. Nevertheless, the stocks have risen 46.96% over the past one year. While a 52-week high of $28.15 was reached on 04/29/25, a 52-week low of $17.38 was recorded on 01/13/25. SMA at 50 days reached $21.29, while 200 days put it at $22.57.
Levels Of Support And Resistance For KNSA Stock
The 24-hour chart illustrates a support level at 23.37, which if violated will result in even more drops to 20.87. On the upside, there is a resistance level at 27.24. A further resistance level may holdings at 28.60. The Relative Strength Index (RSI) on the 14-day chart is 72.57, which indicates overbought technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 2.14, which suggests price will go up in the next trading period. Percent R suggests that price movement has been bullish at 2.68%. Stochastics %K at 96.10% indicates the stock is a selling.
How much short interest is there in Kiniksa Pharmaceuticals International Plc?
A steep rise in short interest was recorded in Kiniksa Pharmaceuticals International Plc stocks on 2025-04-15, growing by 0.24 million shares to a total of 3.32 million shares. Yahoo Finance data shows the prior-month short interest on 2025-03-14 was 3.07 million shares. There was a rise of 7.34%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on April 01, 2020 when BofA/Merrill began covering the stock and recommended ‘”a Buy”‘ rating along with a $25 price target.
